Advanced Search

 

Study ID Status Title Patient Level Data
SCAB2005 Completed A Multicenter, Double-Blind, Placebo-Controlled, Flexible-Dose Evaluation of the Safety and Efficacy of Lamotrigine in the Long Term Treatment of Subjects who have Bipolar Disorder with Rapid Cycling
SCAB2006 Completed A Multicenter, Double-Blind, Placebo-Controlled, Randomized, Flexible-Dose Evaluation of the Safety and Efficacy of Lamotrigine in the Long-Term Prevention of Relapse and Recurrence of Mania and/or Depression in Subjects with Bipolar I Disorder
SCAB2009 Completed A Six-Week, Multicenter, Double-Blind, Placebo-Controlled, Fixed-Dose Evaluation of the Safety and Efficacy of Lamotrigine Compared to Placebo and Lithium in the Treatment of an Acute Manic Episode in Patients who have Bipolar Disorder
SCAB3001 Completed Open Randomized Comparison of Add-on Lamotrigine or Valproate/Carbamazepine Withdrawing to Monotherapy in Patients With Treatment Resistant Epilepsy
SCAB4007 Completed An Open Randomised Comparison of Cognitive and Electrophysiological effects of Lamictal (LTG) or Slow Release Carbamazepine (CBZ) Monotherapy in Newly Diagnosed Patients with Epilepsy
SCB107718 Completed Double blind, randomised, placebo controlled study to evaluate the safety, tolerability and pharmacokinetics of single doses of GSK1014802 and the effect of single doses of GSK1014802 or lamotrigine on resting motor threshold in healthy volunteers
SCO100250 Completed A Randomized, Double-Blind, Parallel Group, 52-Week Study to Compare the Effect of Fluticasone Propionate/Salmeterol Diskus Combination Product 250/50mcg BID with Salmeterol Diskus 50mcg BID on the Annual Rate of Moderate/Severe Exacerbations in Subjects with Chronic Obstructive Pulmonary Disease Study Listed on ClinicalStudyDataRequest.com
SCO100646 Completed Clinical Evaluation of GW815SF for COPD -Assessment of the Effect of Addition of Fluticasone Propionate to Salmeterol Xinafoate 50 after Switching under Double-blinded conditions to GW815SF50/250 in COPD
SCO100648 Completed Clinical Evaluation of GW815SF for Chronic Obstructive Pulmonary Disease (Chronic Bronchitis, Emphysema)“ A Long-term Treatment Study of GW815SF50/500µg in Chronic Obstructive Pulmonary Disease -
SCO104925 Completed A randomized, double-blind placebo-controlled study of treatments with salmeterol, fluticasone propionate and their combination to evaluate novel endpoints in patients with chronic obstructive pulmonary disease Study Listed on ClinicalStudyDataRequest.com
SCO104962 Completed A randomised, double-blind, double dummy, 3 way crossover study evaluating the effects of a combination of Seretide 50/500mcg twice daily plus tiotropium bromide 18mcg once daily compared with the individual agents (tiotropium bromide 18mcg alone and Seretide50/500mcg alone) in the treatment of subjects with COPD Study Listed on ClinicalStudyDataRequest.com
SCO107227 Completed A 12 month open-label randomized parallel group study to investigate the influence of salmeterol xinafoate/fluticasone propionate either in fixed combination or separately via Diskus inhalers on the course of the disease and frequency of exacerbations in subjects with severe and very severe COPD.
SCO20001 Completed A Randomised, Double-Blind, Placebo-Controlled, Cross-Over Study to Investigate the Cardiovascular Pharmacodynamic Effects and Pharmacokinetics of Salmeterol vs Placebo Following 15 Days BD Regimen In COPD Subjects Study Listed on ClinicalStudyDataRequest.com
SCO30002 Completed A multicentre randomised double-blind parallel group placebo controlled study assessing the efficacy and safety of inhaled salmeterol/fluticasone 50/500mcg twice daily, inhaled fluticasone 500mcg twice daily and placebo all administered via MDI in the treatment of patients with COPD Study Listed on ClinicalStudyDataRequest.com
SCO30003 Completed A multicentre, randomised, double-blind, parallel group, placebo-controlled study to investigate the long-term effects of salmeterol/fluticasone propionate (Seretide tm) 50/500mcg BD, salmeterol 50mcg BD and fluticasone propionate 500mcg BD, all delivered via the Diskus tm/Accuhaler tm inhaler, on mortality and morbidity of subjects with chronic obstructive pulmonary disease (COPD) over 3 years of treatment Study Listed on ClinicalStudyDataRequest.com
SCO30005 Completed A 13-week, double-blind, parallel group, multi-centre study to compare the bronchial anti-inflammatory activity of the combination of salmeterol/fluticasone propionate 50/500mcg twice daily compared with placebo twice daily in patients with Chronic Obstructive Pulmonary Disease (COPD) Study Listed on ClinicalStudyDataRequest.com
SCO30006 Completed A randomised, double-blind, parallel-group study to investigate the protective effect of the combination of fluticasone and salmeterol (500/50µg bid via the DISKUS) compared with salmeterol (50µg bid via the DISKUS) on the incidence of moderate to severe exacerbations in patients with severe chr ...
SCO30008 Completed A single-centre, randomised, double-blind, double-dummy, parallel group 3-week study to compare the effect of the salmeterol/fluticasone propionate combination 50/500mcg bd via the DISKUS/ACCUHALER inhaler with tiotropium bromide 18 mcg od via the HANDIHALER inhaler on mucociliary clearance rate in patients with Chronic Obstructive Pulmonary Disease (COPD) Study Listed on ClinicalStudyDataRequest.com
SCO40002 Completed SCO400002/SER9602/COSMIC: One year withdrawal of fluticasone propionate after three months treatment with combined salmeterol/fluticasone propionate in COPD: the COSMIC study.
SCO40011 Completed A Randomized, Double-Blind, Double-Dummy, Parallel-Group, Comparative Clinical Trial Evaluating Fluticasone Propionate/Salmeterol 250/50mcg twice daily via DISKUS to Ipratropium Bromide/Albuterol Sulfate (36mcg/206mcg four times a day) Inhalation Aerosol in Subjects with Chronic Obstructive Pulmonary Disease (COPD) Study Listed on ClinicalStudyDataRequest.com
SCO40012 Completed A Randomized, Double-Blind, Double-Dummy, Parallel-Group, Comparative Clinical Trial Evaluating Fluticasone Propionate/Salmeterol Xinafoate (250/50mcg twice daily via Diskus) to Ipratropium Bromide/Albuterol Sulfate (36mcg/206mcg four times a day) Inhalation Aerosol in Subjects with Chronic Obstructive Pulmondary Disease (COPD) Study Listed on ClinicalStudyDataRequest.com
SCO40030 Completed A Randomized, Double Blind, Placebo Controlled, Parallel Group Clinical Trial Evaluating the Effect of the Fluticasone/Salmeterol Combination Product 250/50mcg twice daily via DISKUS and Salmeterol 50 mcg twice daily via DISKUS on Lung Hyperinflation in Subjects with COPD. Study Listed on ClinicalStudyDataRequest.com
SCO40034 Completed A multicentre, randomised, double-blind, double dummy, parallel group 12-week exploratory study to compare the effect of the salmeterol/fluticasone propionate combination product (SERETIDE™) 50/500mcg bd via the DISKUS™/ACCUHALER™ inhaler with tiotropium bromide 18 mcg od via the Handihaler inha ...
SCO40036 Completed Multicentre, Randomised, Double-Blind, Double Dummy, Parallel Group, 104-week Study to Compare the Effect of the Salmeterol/Fluticasone Propionate Combination Product (SERETIDE*) 50/500mcg Delivered Twice Daily via the DISKUS*/ACCUHALER* Inhaler with Tiotropium Bromide 18 mcg Delivered Once Daily via the HandiHaler Inhalation Device on the Rate of Health Care Utilisation Exacerbations in Subjects with Severe Chronic Obstructive Pulmonary Disease (COPD) Study Listed on ClinicalStudyDataRequest.com
SCO40041 Completed A Randomized, Double-Blind, Parallel-Group Clinical Trial Evaluating the Effect of the fluticasone propionate/salmeterol Combination Product 250/50mcg twice daily via DISKUS® inhaler versus salmeterol 50mcg twice daily via DISKUS® inhaler on Bone Mineral Density in Subjects with Chronic Obstructive Pulmonary Disease (COPD) Study Listed on ClinicalStudyDataRequest.com

 

 

For more information on this register please email GSKClinicalSupportHD@gsk.com

GSK-sponsored clinical studies are those for which GSK is ultimately responsible for all aspects of the study even if some or all of these activities are transferred to another party.
GSK-sponsored clinical trials are those for which GSK is ultimately responsible for all aspects of the study even if some or all of these activities are transferred to another party.

ClinicalTrial.gov is a database that provides summary protocol information for ongoing clinical trials.

IFPMA.org is a search portal provided by the International Federation of Pharamceutical Manufacturers & Associations (IFPMA).

This portal provides a single entry point to search for industry sponsored clinical trials which are on existing registers and databases.

EU Clinical Trials Register is a database of all clinical trials commencing in the European Community from 1 May 2004 onwards. It has been established in accordance with Directive 2001/20/EC.